Palisade bio announces first patient enrolled and dosed in pivotal phase 3 study evaluating lb1148 for postoperative return of bowel function

Carlsbad, calif., aug. 17, 2022 (globe newswire) -- palisade bio, inc. (nasdaq: pali), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, today announced the first patient has been dosed in its phase 3 study evaluating lb1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.
PALI Ratings Summary
PALI Quant Ranking